Jan Lubinski | Conference 2019 Skip to main content

Prof. Jan Lubinski M.D.

Pomeranian Academy of Medicine, Szczecin


Milestone improvements on prevention and treatment of cancers based on knowledge of patients' genetic changes

Pomeranian Academy of Medicine, Szczecin        

M.D.    1971-1977    Medicine

Ph.D.    1980        Pathology Habilitation    

1989    Pathology-Molecular Genetics

1980, 1985        Surgical Pathology
1989     Clinical and Molecular Genetics of Hereditary Cancer
2003    Clinical Genetics
2007    Medical Laboratory Genetics
Research and professional experience:        
1977-1985    Assistant, Dept Pathomorphology, Pomeranian Academy of Medicine, Szczecin
1981-1982    Visiting Scientist, French Government Fellowship, Pasteur Institute, Paris
1985-1989    Assistant Professor, Dept. Tumour Pathology, Pomeranian Academy of Medicine, Szczecin.
1987-1988    Visiting Scientist, Fulbright Fellowship. The Wistar Institute, Philadelphia
IV-VII 1989 and 1991    Visiting Scientist, The Fels Institute for Cancer Research and Molecular Biology, Temple University, Jefferson Cancer Institute, Philadelphia
1989    Associate Professor, Head of Dept. of Genetics and Pathology, Pomeranian Academy of Medicine
1992    Professor
1992    Organiser and head of Regional Hereditary Cancer Centre, Szczecin
1993-1999    Rector for Science, Pomeranian Academy of Medicine, Szczecin
I-II 1994    Visiting Scientist, Jefferson Centre Institute, Philadelphia
1998    Author and coordinator of project on development of Polish Network of Hereditary Cancer Centres.
1998 – 2011    National Consultant of Clinical Genetics
1999    Author and coordinator of project on development of cancer family syndrome registries in Eastern Europe
2003 -     Head of International Hereditary Cancer Center of Pomeranian Medical University
2003 -     Founder and one of editors-in-chief of the journal Hereditary Cancer in Clinical Practice
2005 -     Polish representative for the Contact Group to ETP Innovative Medicine, European Commission
2005    Doctor Honoris Causa of Rīga Stradiņš University, Rīga, Latvia
2005 -     Head of Polish Technology Platform for Innovative Medicine
2006 - 2011    European Society of Human Genetics Board Member

2010 -     Clinical Genetics - Member of Editorial Board

2010 - 2014    Member of Scientific Council of the National Center for Research and Development
2015 – 2018   Member of Scientific Council of the Institute of Human Genetics, Polish Academy of Sciences
Number of publications: ~650
Hirsch-index: 59, no of citations: 13.795, without self-citations: 12.542

List of patents granted:
9 international patents granted:
1.    Determining a predisposition to cancer - Patent No. 7,851,162 B2 (USA), EP05704666.6 (European).
2.    Determining a predisposition to cancer (CHEK2) - Patent No. 7,407,755 B2 (USA),
3.    Determining a predisposition to cancer (NBS1) - Patent No. 7,319,007 B2 (USA),
4.    Determining a predisposition to cancer (NBS1) - Patent No. 7,745,133 (USA),
5.    Fast assignment of adequate neoadjuvant chemotherapy for breast cancer patients based on the identification of constitutional BRCA1 mutations – patent no 2008/10173 (South Africa)
6.    Method for determining reduced predisposition to cancer based on genetic profile - Patent 61/069,403 (USA)
7.    Pharmaceutical composition and methods for the prevention of breast and ovarian cancer - Patent No. 2006/02081 (South Africa),
8.    Polymorphism in the human NBS1 gene useful in diagnostic of inherited predisposition to cancer - Patent No. 011608 (Euroasia),
9.    Polymorphism in the human NBS1 gene useful in diagnostics of inherited predisposition to prostate cancer and lobular invasive breast cancer - patent no 93344 (Ukraine).

15 Polish patents granted

Summarisation of the most important achievements:
1.    Creation of International Hereditary Cancer Centre and Department of Genetics and Pathology of Pomeranian Medical University with significant international position due to achievements mainly on diagnosis and prophylactics of hereditary cancers elaborated in Poland in collaboration with scientists from other countries.
2.    Publication together with his team around 200 publications on hereditary cancers during the last 10 years. Most of them are papers published in SCI journals including JAMA (Impact Factor 23,33), Journal of the National Cancer Institute (Impact Factor 15,171), American Journal of Human Genetics (Impact Factor 12,649), Journal of Clinical Oncology (Impact Factor 11,81), PNAS (Impact Factor 10,231), Lancet Oncology (Impact Factor 7,855), Cancer Research (Impact Factor 7,616).
3.    Realisation of numerous international collaborative studies. Prof. Lubinski has been an author and coordinator of the projects:
   MZ/NIH-96-287 – Genomic deletions as markers for renal carcinoma diagnosis; U.S.-Poland Maria Sklodowska–Curie Joint Fund II.
   ERB 3510-PL-92-2713 – Molecular genetic analyses in diagnosis of renal cell carcinoma – EC project;
    MZ/HHS-91–75 - Molecular genetic analyses in tumour diagnosis; U.S.-Poland Maria Sklodowska–Curie Joint Fund II.
   QLRI-CT-1999-00063 - Development of network of cancer family syndrome registries in Eastern Europe 5th Framework Programme of European Union
    MTKD-CT-2004-510114 - Identification of new cancer susceptibility genes by linkage analyses in Polish families with aggregation of breast or colorectal cancers,  6th Framework Programme of European Union
4.    Co-authorship of numerous international patent applications.
5.    Population screening for familial cancers – family doctors and nurses performed screening for cancer family history of all inhabitants – population of 1.5 million, of West-Pomeranian Region in Poland. Programme of entire population screening for all types of familial cancer is, according to our knowledge, the first in the world.
6.    Publication under auspices of UICC peer-reviewed journal Hereditary Cancer in Clinical Practice (since 2008 on SCI list), editors-in-chief: J. Lubinski, R. Scott, R. Sijmons.
7.    Development of registry unique at worldwide scale of cancer family syndromes with the following parameters:
-    almost 5,000 of diagnosed and registered BRCA1 mutation carriers – the largest number in the world,
-    more than 32,000 registered families with other cancer family syndromes or strong aggregation of malignancies with biological samples available from at least 1 affected relative,
-    more than 274,000 DNAs from cancer patients or their relatives,
-    almost 7,000 cell lines from BRCA1 mutation carriers,
-    pedigree data from 1,258,000 persons – more than 80% of Regional Health Care Company collected during realisation of 1st worldwide project for inherited cancer prevention.
8.    The first world-wide demonstration of genetic contribution to all cancers using the model of breast cancers from homogenous Polish population (Breast Cancer Res Treat 2008)